PDCI is very excited to announce the promotion of Jennifer Haig to the position of Associate Director, HTA and Health Economics. This promotion is effective immediately.
Jen has been with PDCI for 18 months, and in that time has ... Read More
PDCI is excited to announce and welcome Kimberly Robinson as the newest member of the PDCI team. Kimberly will be joining as the Director of Pricing and Market Access effective April 1, 2019 and will be responsible for the leadership of PDCI’s Pricing/PMPRB team. She will be based in the ... Read More
Bill Morneau released his fourth Federal Budget in the House of Commons at 4pm today.
Year in Review:
In 2018, the federal budget established an independent Advisory Council on the Implementation of National Pharmacare. Over the past year, the Advisory Council, lead by Dr. Eric Hoskins, released a discussion paper in ... Read More
Each month the pCPA issues an update on the previous month’s negotiation activity. In Table 1 below you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest.... Read More
On February 28, 2019, Health Canada and CADTH, with INESSS participating as an observer, announced a new joint Early Parallel Scientific Advice collaboration. The initiative seeks to provide more timely access to medicines for Canadians. Through this initiative, drug sponsors will obtain advice in parallel from Health Canada and ... Read More
CADTH is launching a new Patient and Community Advisory Committee
After talks with patient groups this past fall, CADTH is creating a 12-person advisory committee to discuss the experiences of patients and family caregivers in Canada. They invite nominations for those with extensive experience as a patient or family caregiver in ... Read More
The Office of the pan-Canadian Pharmaceutical Alliance (pCPA) assesses brand name drug products for public funding either collectively or individually at the provincial and territorial levels. Each month the pCPA issues an update on the previous month’s negotiation activity. A file is complete once a Letter of Intent (LOI) is ... Read More
In keeping with our continuing efforts to support transparency and share input submissions for public policy consultations, PDCI is hosting responses to a recent CADTH survey that was conducted on behalf of the Provincial/Territorial (P/T) Expensive Drugs for Rare Disease Working Group (EDRD WG). The EDRD WG sought public feedback ... Read More
On February 6, 2019, CADTH announced a new collaboration with England’s NICE (National Institute for Health and Care Excellence) to offer Parallel Scientific Advice to pharmaceutical companies. Participating pharmaceutical companies will receive advice simultaneously from CADTH and NICE to facilitate evidence generation for the Canadian and English markets.
This new opportunity ... Read More
